Showing 1 - 5 results of 5 for search 'Laura Devis‐Jauregui', query time: 0.03s Refine Results
  1. 1
    In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma.

    In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in... by Catherine Murphy, Laura Devis-Jauregui, Ronja Struck, Ariadna Boloix, Ciara Gallagher, Cian Gavin, Federica Cottone, Aroa Soriano Fernandez, Stephen Madden, Josep Roma, Miguel F Segura, Olga Piskareva

    Published 2024-01-01
    Get full text
    Article
  2. 2
    In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma

    In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in... by Catherine Murphy, Laura Devis-Jauregui, Ronja Struck, Ariadna Boloix, Ciara Gallagher, Cian Gavin, Federica Cottone, Aroa Soriano Fernandez, Stephen Madden, Josep Roma, Miguel F. Segura, Olga Piskareva

    Published 2024-01-01
    Get full text
    Article
  3. 3
    Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program

    Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program by Carlos Jiménez, Roberta Antonelli, Mariona Nadal-Ribelles, Laura Devis-Jauregui, Pablo Latorre, Carme Solé, Marc Masanas, Adrià Molero-Valenzuela, Aroa Soriano, Josep Sánchez de Toledo, David Llobet-Navas, Josep Roma, Francesc Posas, Eulàlia de Nadal, Soledad Gallego, Lucas Moreno, Miguel F. Segura

    Published 2022-09-01
    Get full text
    Article
  4. 4
    The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

    The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models by Marc Masanas, Nuria Masiá, Leticia Suárez‐Cabrera, Mireia Olivan, Aroa Soriano, Blanca Majem, Laura Devis‐Jauregui, Rebeca Burgos‐Panadero, Carlos Jiménez, Pau Rodriguez‐Sodupe, Ariadna Boloix, Ignasi Toledano, Gabriela Guillén, Alexandra Navarro, David Llobet‐Navas, Alberto Villanueva, Josep Sánchez de Toledo, Josep Roma, Rosa Noguera, Lucas Moreno, Rolf Krauss, Soledad Gallego, Anna Santamaria, Miguel F. Segura

    Published 2021-10-01
    Get full text
    Article
  5. 5
    Generation and Integrated Analysis of Advanced Patient‐Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer

    Generation and Integrated Analysis of Advanced Patient‐Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer by Laura Devis‐Jauregui, August Vidal, Laura Plata‐Peña, Maria Santacana, Sandra García‐Mulero, Nuria Bonifaci, Eulàlia Noguera‐Delgado, Nuria Ruiz, Marta Gil, Eduard Dorca, Francisco J. Llobet, Laura Coll‐Iglesias, Katja Gassner, Maria Martinez‐Iniesta, Ruth Rodriguez‐Barrueco, Marc Barahona, Lola Marti, Francesc Viñals, Jordi Ponce, Rebeca Sanz‐Pamplona, Josep M. Piulats, Ana Vivancos, Xavier Matias‐Guiu, Alberto Villanueva, David Llobet‐Navas

    Published 2023-01-01
    Get full text
    Article

Search Tools: